Ocular Therapeutix OCUL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$88.61M-38.3% | -$64.65M-33.6% | -$69.42M-90.2% | -$67.81M-54.9% | -$64.05M+1.2% | ||
| $1.28M+30.8% | $1.25M+31.1% | $1.07M+11.5% | $1.03M+7.3% | $981K+6.6% | ||
| $15.58M+49.0% | $11.36M+57.8% | $11.69M+76.0% | $9.68M-14.3% | $10.46M+31.1% | ||
| $1.38M-3.8% | $495K-14.1% | $758K+22.1% | $708K+24.4% | $1.44M-27.0% | ||
| -$4.87M— | —— | —— | $29K— | —— | ||
| -$6.3M+12.1% | -$118K-105% | —— | —— | -$7.17M-2,053% | ||
| $173K-24.5% | $76K-88.0% | $449K— | -$230K— | $229K-14.9% | ||
| $3.72M+53,029% | -$1.35M— | -$1.27M— | $1.73M+172% | $7K-99.6% | ||
| -$8.44M-64.1% | $2.18M-48.3% | $5.38M— | $2.84M— | -$5.15M+63.3% | ||
| $357K+109% | —— | -$522K-107% | -$1.05M+32.3% | -$3.93M-2,973% | ||
| —— | —— | —— | -$64K-3.2% | -$64K-8.5% | ||
| $1.77M+791% | -$759K-2,348% | -$642K-43.6% | $0+100% | -$256K+50.3% | ||
| -$65.99M-47.7% | -$54.25M-37.6% | -$50.73M-38.7% | -$55.24M-123% | -$44.67M-31.8% | ||
| $4.66M+141% | $2.84M+1,305% | $5.99M+6,634% | $1.25M+67.8% | $1.93M+658% | ||
| -$4.66M-141% | -$2.84M-1,305% | -$5.99M-6,634% | -$1.12M-50.3% | -$1.93M-658% | ||
| $294K-93.0% | $2.94M-26.4% | $10.36M— | $3.07M— | $4.18M-98.7% | ||
| $294K-93.0% | $449.38M+9,857% | $10.36M+148% | $97.81M+4,354% | $4.18M-98.7% | ||
| -$70.36M-65.9% | $392.29M— | -$46.36M— | $41.45M— | -$42.42M-115% | ||
| $2.19M+2.3% | $2.24M-32.7% | $2.34M-10.2% | $2.31M-12.2% | $2.14M-83.5% | ||
| $1.38M-3.8% | $495K-14.1% | $758K+22.1% | $708K+24.4% | $1.44M-27.0% | ||
| $1.46M+249% | —— | -$1.45M-120% | -$641K+78.8% | -$978K+81.0% | ||
| $1.86M+1,687% | -$696K— | -$549K-76.5% | $0+100% | -$117K+71.7% | ||
| $1.77M+791% | -$759K-2,348% | -$642K-43.6% | $0+100% | -$256K+50.3% | ||
| $357K+109% | —— | -$522K-107% | -$1.05M+32.3% | -$3.93M-2,973% | ||
| $1.33M+135% | —— | $1.62M+4,797% | —— | $564K+43.9% | ||
| $1.77M+791% | -$759K-2,348% | -$642K-43.6% | $0+100% | -$256K+50.3% | ||
| $2.51M— | —— | —— | —— | —— | ||
| -$70.66M-51.6% | -$57.09M-44.0% | -$56.72M-54.8% | -$56.48M-121% | -$46.6M-36.5% | ||
| -$70.66M-51.6% | -$57.09M-44.0% | -$56.72M-54.8% | -$56.48M-121% | -$46.6M-36.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ocular Therapeutix generate?
- Ocular Therapeutix (OCUL) generated -$226.2M in operating cash flow over the trailing twelve months.
- What is Ocular Therapeutix's free cash flow?
- After $14.7M of capital expenditures, Ocular Therapeutix's free cash flow was -$240.9M over the trailing twelve months, down 62.3% year over year.
- Where does Ocular Therapeutix's cash flow data come from?
- Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
